Cargando…
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Checkpoint protein inhibitor antibodies (CPI), including cytotoxic T-lymphocyte-associated antigen 4 inhibitors (ipilimumab, tremelimumab) and the programmed cell death protein 1 pathway/programmed cell death protein 1 ligand inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab), have ente...
Autores principales: | Lemiale, Virginie, Meert, Anne-Pascale, Vincent, François, Darmon, Michael, Bauer, Philippe R., Van de Louw, Andry, Azoulay, Elie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358632/ https://www.ncbi.nlm.nih.gov/pubmed/30707321 http://dx.doi.org/10.1186/s13613-019-0487-x |
Ejemplares similares
-
Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases
por: Assoun, Sandra, et al.
Publicado: (2019) -
Checkpoint inhibitors: What gastroenterologists need to know
por: Ahmed, Monjur
Publicado: (2018) -
In-hospital and day-120 survival of critically ill solid cancer patients after discharge of the intensive care units: results of a retrospective multicenter study—A Groupe de recherche respiratoire en réanimation en Onco–Hématologie (Grrr-OH) study
por: Vincent, François, et al.
Publicado: (2018) -
(1, 3)-β-D-glucan assay for diagnosing invasive fungal infections in critically ill patients with hematological malignancies
por: Azoulay, Elie, et al.
Publicado: (2016) -
Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era
por: Van de Louw, Andry, et al.
Publicado: (2021)